ID   A2L/AH
AC   CVCL_X202
DR   Wikidata; Q54606627
RX   PubMed=3008992;
RX   PubMed=6088881;
RX   PubMed=6324641;
CC   Doubling time: 30 hours (PubMed=6088881).
CC   Selected for resistance to: ChEBI; CHEBI:63486; 8-azaguanine.
CC   Transformant: NCBI_TaxID; 10376; Epstein-Barr virus (EBV).
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_X201 ! A2L
HI   CVCL_X200 ! Ad-AH
CA   Hybrid cell line
DT   Created: 17-07-14; Last updated: 21-03-23; Version: 5
//
RX   PubMed=3008992;
RA   Takimoto T., Sato H., Ogura H., Miyawaki T., Glaser R.;
RT   "Superinfection of epithelial hybrid cells (D98/HR-1, NPC-KT, and
RT   A2L/AH) with Epstein-Barr virus and the relationship to the C3d
RT   receptor.";
RL   Cancer Res. 46:2541-2544(1986).
//
RX   PubMed=6088881; DOI=10.1093/jnci/73.3.711;
RA   Takimoto T., Ogura H., Ohno S., Umeda R., Hatano M.;
RT   "Tumorigenicity of nasopharyngeal carcinoma hybrid cell line.";
RL   J. Natl. Cancer Inst. 73:711-715(1984).
//
RX   PubMed=6324641; DOI=10.1177/000348948409300213;
RA   Takimoto T., Furukawa M., Hatano M., Umeda R.;
RT   "Epstein-Barr virus nuclear antigen-positive nasopharyngeal hybrid
RT   cells.";
RL   Ann. Otol. Rhinol. Laryngol. 93:166-169(1984).
//